Pharmacies told to stop making custom versions of Wegovy and Zepbound after shortages declared officially over ...

T he US Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk are now in an attempt to making more ...

The global pharmaceutical industry could generate about $1.2 trillion in sales in 2025, according to Statista, and projections call for 4.7% annual growth through 2029. The cancer treatment segment ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Which European healthcare stocks are most attractive right now? Seeking Alpha analysts offer their picks. Read more here.

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Both the FDA and Novo Nordisk are advising patients and providers to check their supplies of Ozempic for counterfeit product. Individuals in possession of a counterfeit product are urged to call Novo ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...